Literature DB >> 18528931

Clinical features and management of primary sclerosing cholangitis.

Marina-G Silveira1, Keith-D Lindor.   

Abstract

Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts, resulting in cirrhosis and need for liver transplantation and reduced life expectancy. The majority of cases occur in young and middle-aged men, often in association with inflammatory bowel disease. The etiology of primary sclerosing cholangitis includes immune-mediated components and elements of undefined nature. No effective medical therapy has been identified. The multiple complications of primary sclerosing cholangitis include metabolic bone disease, dominant strictures, bacterial cholangitis, and malignancy, particularly cholangiocarcinoma, which is the most lethal complication of primary sclerosing cholangitis. Liver transplantation is currently the only life-extending therapeutic alternative for patients with end-stage disease, although recurrence in the allografted liver has been described. A PSC-like variant attracting attention is cholangitis marked by raised levels of the immunoglobulin G4 subclass, prominence of plasma cells within the lesions, and steroid responsiveness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18528931      PMCID: PMC2716588          DOI: 10.3748/wjg.14.3338

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  163 in total

Review 1.  Management of primary sclerosing cholangitis.

Authors:  Young-Mee Lee; Marshall M Kaplan
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

Review 2.  Future directions in the medical treatment of primary sclerosing cholangitis: the need for combination drug therapy.

Authors:  D G Fong; K D Lindor
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

3.  Bone disease in liver transplant recipients: incidence, timing, and risk factors.

Authors:  M K Porayko; R H Wiesner; J E Hay; R A Krom; E R Dickson; S Beaver; L Schwerman
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

5.  Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period.

Authors:  N De Maria; A Colantoni; E Rosenbloom; D H Van Thiel
Journal:  Hepatogastroenterology       Date:  1996 Nov-Dec

6.  Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.

Authors:  Adolf Stiehl; Gerda Rudolph; Petra Klöters-Plachky; Peter Sauer; Siegfried Walker
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

7.  A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis.

Authors:  T A Knox; M M Kaplan
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

8.  Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.

Authors:  U Broomé; R Löfberg; B Veress; L S Eriksson
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

9.  IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis?

Authors:  Yoh Zen; Kenichi Harada; Motoko Sasaki; Yasunori Sato; Koichi Tsuneyama; Joji Haratake; Hiroshi Kurumaya; Kazuyoshi Katayanagi; Shinji Masuda; Hideki Niwa; Hideo Morimoto; Atsuo Miwa; Akio Uchiyama; Bernard C Portmann; Yasuni Nakanuma
Journal:  Am J Surg Pathol       Date:  2004-09       Impact factor: 6.394

10.  Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis.

Authors:  R W Chapman; M Cottone; W S Selby; H A Shepherd; S Sherlock; D P Jewell
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

View more
  11 in total

1.  Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.

Authors:  Anna Baghdasaryan; Thierry Claudel; Astrid Kosters; Judith Gumhold; Dagmar Silbert; Andrea Thüringer; Katharina Leski; Peter Fickert; Saul J Karpen; Michael Trauner
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

Review 2.  Liver biopsy diagnosis of hepatitis: clues to clinically-meaningful reporting.

Authors:  Elizabeth M Brunt
Journal:  Mo Med       Date:  2010 Mar-Apr

3.  The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice.

Authors:  Peter Fickert; Andrea Thueringer; Tarek Moustafa; Dagmar Silbert; Judith Gumhold; Oleksiy Tsybrovskyy; Margitta Lebofsky; Hartmut Jaeschke; Helmut Denk; Michael Trauner
Journal:  Lab Invest       Date:  2010-04-05       Impact factor: 5.662

4.  Extensively spreading intraepithelial bile duct carcinoma causing multiple bile duct strictures: report of three cases.

Authors:  Takahiro Tsuchikawa; Satoshi Kondo; Satoshi Hirano; Eiichi Tanaka; Kentaro Kato; Joe Matsumoto; Kanako C Kubota; Toshiaki Shichinohe
Journal:  Surg Today       Date:  2011-10-04       Impact factor: 2.549

5.  Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.

Authors:  Emmanouil Sinakos; Hanns-Ulrich Marschall; Kris V Kowdley; Alex Befeler; Jill Keach; Keith Lindor
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

6.  Individuals with Primary Sclerosing Cholangitis Have Elevated Levels of Biomarkers for Apoptosis but Not Necrosis.

Authors:  Howard C Masuoka; Raj Vuppalanchi; Ross Deppe; Phelan Bybee; Megan Comerford; Suthat Liangpunsakul; Marwan Ghabril; Naga Chalasani
Journal:  Dig Dis Sci       Date:  2015-07-21       Impact factor: 3.199

Review 7.  Glucocorticosteroids for primary sclerosing cholangitis.

Authors:  Vanja Giljaca; Goran Poropat; Davor Stimac; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

8.  Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis.

Authors:  Seth N Sclair; Ester Little; Cynthia Levy
Journal:  Clin Transl Gastroenterol       Date:  2015-08-27       Impact factor: 4.488

9.  Frequency and risk factors of primary sclerosing cholangitis among patients with inflammatory bowel disease in North-East of Iran.

Authors:  Ahmad Khosravi Khorashad; Mohammad Khajedaluee; Elham Mokhtari Amirmajdi; Ali Bahari; Mohammad Reza Farzanehfar; Mitra Ahadi; Siavash Abedini; Mohammad Reza Abdollahi; Rosita Vakili; Hassan Vossoughi Nia
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015

10.  Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis.

Authors:  Annika Gauss; Peter Sauer; Adolf Stiehl; Christian Rupp; Johannes Krisam; Yvonne Leopold; Petra Kloeters-Plachky; Wolfgang Stremmel; Daniel Gotthardt
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.